Literature DB >> 17885294

Causes of death in hospitalized adults with a premortem diagnosis of tuberculosis: an autopsy study.

Neil A Martinson1, Alan Karstaedt, W D Francois Venter, Tanvier Omar, Peter King, Tumi Mbengo, Else Marais, James McIntyre, Richard E Chaisson, Martin Hale.   

Abstract

OBJECTIVE: To ascertain the immediate and underlying causes of death in adults who died in hospital with a premortem diagnosis of tuberculosis.
DESIGN: Causes of death were assessed independently by internists and pathologists in 50 adults admitted to two Soweto hospitals who died 24 h or more after admission. Detailed record reviews and complete autopsies, including HIV tests when not performed premortem, were performed. In addition, a variety of postmortem microbiological tests were performed.
RESULTS: Forty-seven patients had HIV infection; all were antiretroviral naive. Their median age was 34.5 years, median CD4 cell count was 48 cells/microl and median length of hospitalization before death was 6 days. Autopsy confirmed the premortem diagnosis of tuberculosis in 37 HIV-infected patients (79%), whereas 10 (21%) did not demonstrate tuberculosis. Bronchopneumonia and cytomegalovirus pneumonitis were the leading pathologies in these 10 patients. In 47 HIV-infected cadavers immediate or contributory causes of death were: extensive pulmonary tuberculosis, 32 (68%); disseminated tuberculosis, 28 (60%); bacterial pneumonia, 13 (26%); cytomegalovirus pneumonitis in seven (15%); cytomegalovirus DNA was found in 31 (66%) and Pneumocystis pneumonia was found in five cadavers (11%). The lung, followed by lymph nodes, liver and kidney, were the commonest sites of tuberculosis. Mycobacterium tuberculosis was cultured from 19 spleens, one of which was multidrug resistant, and Salmonella spp. was cultured from 11 splenic specimens.
CONCLUSION: We demonstrated disseminated, extensive tuberculosis associated with advanced HIV disease. Severe bacterial infections, including salmonellosis, were the leading co-morbidity, suggesting that hospitalized HIV-infected adults in whom tuberculosis is suspected may benefit from broad-spectrum antibiotic therapy.

Entities:  

Mesh:

Year:  2007        PMID: 17885294     DOI: 10.1097/QAD.0b013e3282eea47f

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  53 in total

1.  Scaling up antiretroviral therapy in developing countries: what are the benefits and challenges?

Authors:  A Boulle; N Ford
Journal:  Sex Transm Infect       Date:  2007-12       Impact factor: 3.519

Review 2.  Economic challenges associated with tuberculosis diagnostic development.

Authors:  Colleen F Hanrahan; Maunank Shah
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2014-04-28       Impact factor: 2.217

3.  Cost-effectiveness of novel algorithms for rapid diagnosis of tuberculosis in HIV-infected individuals in Uganda.

Authors:  Maunank Shah; David Dowdy; Moses Joloba; Willy Ssengooba; Yukari C Manabe; Jerrold Ellner; Susan E Dorman
Journal:  AIDS       Date:  2013-11-28       Impact factor: 4.177

Review 4.  Salmonella infection: Interplay between the bacteria and host immune system.

Authors:  Jonathan R Kurtz; J Alan Goggins; James B McLachlan
Journal:  Immunol Lett       Date:  2017-07-15       Impact factor: 3.685

5.  The prevalence and drug sensitivity of tuberculosis among patients dying in hospital in KwaZulu-Natal, South Africa: a postmortem study.

Authors:  Ted Cohen; Megan Murray; Kristina Wallengren; Gonzalo G Alvarez; Elizabeth Y Samuel; Douglas Wilson
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

6.  The risk and timing of tuberculosis diagnosed in smear-negative TB suspects: a 12 month cohort study in Harare, Zimbabwe.

Authors:  Munyaradzi Dimairo; Peter MacPherson; Tsitsi Bandason; Abbas Zezai; Shungu S Munyati; Anthony E Butterworth; Stanley Mungofa; Simba Rusikaniko; Katherine Fielding; Peter R Mason; Elizabeth L Corbett
Journal:  PLoS One       Date:  2010-07-28       Impact factor: 3.240

7.  Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults.

Authors:  D Sun; S Dorman; M Shah; Y C Manabe; V M Moodley; M P Nicol; D W Dowdy
Journal:  Int J Tuberc Lung Dis       Date:  2013-04       Impact factor: 2.373

Review 8.  Epidemiology of HIV-associated tuberculosis.

Authors:  Stephen D Lawn; Gavin Churchyard
Journal:  Curr Opin HIV AIDS       Date:  2009-07       Impact factor: 4.283

9.  Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Authors:  Dominique J Pepper; Suzaan Marais; Robert J Wilkinson; Feriyl Bhaijee; Gary Maartens; Helen McIlleron; Virginia De Azevedo; Helen Cox; Cheryl McDermid; Simiso Sokhela; Janisha Patel; Graeme Meintjes
Journal:  BMC Infect Dis       Date:  2010-03-30       Impact factor: 3.090

10.  Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial.

Authors:  Andrew J Nunn; Peter Mwaba; Chifumbe Chintu; Alwyn Mwinga; Janet H Darbyshire; Alimuddin Zumla
Journal:  BMJ       Date:  2008-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.